Follow
Melissa J Barber
Melissa J Barber
Verified email at g.harvard.edu - Homepage
Title
Cited by
Cited by
Year
Estimated costs of production and potential prices for the WHO Essential Medicines List
AM Hill, MJ Barber, D Gotham
BMJ global health 3 (1), e000571, 2018
1042018
Production costs and potential prices for biosimilars of human insulin and insulin analogues
D Gotham, MJ Barber, A Hill
BMJ global health 3 (5), e000850, 2018
882018
Price of a hepatitis C cure: Cost of production and current prices for direct-acting antivirals in 50 countries
MJ Barber, D Gotham, G Khwairakpam, A Hill
Journal of Virus Eradication 6 (3), 100001, 2020
552020
Global access of rifabutin for the treatment of tuberculosis–why should we prioritize this?
N Rockwood, M Cerrone, M Barber, AM Hill, AL Pozniak
African Journal of Reproduction and Gynaecological Endoscopy 22 (7), 2019
262019
How the MDGs gave up on measuring access to medicines
D Gotham, KH Onarheim, MJ Barber
The Lancet Global Health 4 (5), e296-e297, 2016
232016
Estimation of cost-based prices for injectable medicines in the WHO Essential Medicines List
D Gotham, MJ Barber, AM Hill
BMJ open 9 (9), e027780, 2019
212019
Estimated sustainable cost-based prices for diabetes medicines
MJ Barber, D Gotham, H Bygrave, C Cepuch
JAMA Network Open 7 (3), e243474-e243474, 2024
112024
Generic treatments for HIV, HBV, HCV, TB could be mass produced for< $90 per patient
A Hill, M Barber, D Gotham, J Fortunak, S Nath, A Pozniak
J Int Aids Soc 20 (Suppl 5), 2017
102017
Open letter to the candidates for Director-General of WHO: will you support a patient-centred R&D agreement?
MJ Barber, D Gotham, J Muntanyà, T Balasubramaniam
The Lancet Global Health 5 (2), e135-e136, 2017
72017
Improving affordability of new essential cancer medicines
E t'Hoen, S Meyer, P Durisch, W Bannenberg, K Perehudoff, T Reed, ...
Lancet Oncology 20 (8), 1052-1054, 2019
62019
How a US-UK trade agreement could affect NHS drug prices
D Gotham, MJ Barber, AM Hill
BMJ 369, 2020
52020
Potential price reductions for cancer medicines on the WHO Essential Medicines List
M Barber, D Gotham, A Hill
European Journal of Cancer 1 (72), S119, 2017
32017
Hepatitis C could now be cured for under US $100 per person: analysis of mass generic production of Direct Acting Antivirals
AM Hill, D Gotham, M Barber, A Pozniak, JM Fortunak
Hepatology 63 (1 SUPP), 482A-482A, 2016
32016
Rapidly falling costs for new hepatitis C direct-acting antivirals (DAAs): potential for universal access
D Gotham, M Barber, J Fortunak, A Pozniak, A Hill
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY 19, 2016
32016
COVID-19 antivirals must not affect HIV drug supply
M Barber, A Sarpatwari, C Cepuch
The Lancet HIV 9 (1), e7-e9, 2022
22022
Young people have a new vision for essential medicines
SR Mishra, SWS Li, KH Onarheim, F Lander, MJ Barber, A Sharma, ...
The Lancet Diabetes & Endocrinology 4 (9), 733-734, 2016
22016
Medicines, Markets, and the State
M Barber
Harvard University, 2023
12023
The Road to Elimination of Hepatitis C: Costs Per Cure Fall to US $32 Per Person
AM Hill, M Barber, G Khwairakpam, D Gotham
HEPATOLOGY 70, 352A-352A, 2019
12019
Unexplained rises in UK cancer drug prices between 2011 and 2016
A Hill, M Barber
European Journal of Cancer 1 (72), S113-S114, 2017
12017
Estimating The Effects Of COVID-19 On Globalized Markets For Active Pharmaceutical Ingredients: Study examines the effects of the COVID-19 pandemic on global markets for active …
M Barber, R Ramachandran, S Moon
Health Affairs 43 (7), 959-969, 2024
2024
The system can't perform the operation now. Try again later.
Articles 1–20